相关实验视频

Updated: Jun 27, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

逆转激进淋巴瘤的潮流:液体活检用于风险适应的治疗策略

Steven Wang¹, Florent Mouliere², D Michiel Pegtel³

¹Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, 1117, Amsterdam, The Netherlands; Imaging and Biomarkers, Cancer Center Amsterdam, De Boelelaan, 1117, Amsterdam, The Netherlands.

Trends in molecular medicine

|May 1, 2024

概括

使用循环中的核酸进行液体活检,有望改善扩散型大B细胞淋巴瘤 (DLBCL) 的风险分层. 这种微创方法可以帮助识别耐药或复发 (R/R) 疾病患者进行个性化治疗.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子诊断学分子诊断

背景情况:

扩散性大B细胞淋巴瘤 (DLBCL) 呈现出显著的异质性,使风险分层和监测复杂化.
目前的风险分层工具 (IPI,分子分析,成像) 对患者的预测结果的准确性有限.
随着治疗环境的不断变化,需要改进的方法来识别患有耐药或复发 (R/R) 疾病风险的患者.

研究的目的:

审查DLBCL患者液体活检策略的进展.
突出液体活检在DLBCL治疗中的临床潜力.
为DLBCL的生物标志物导向试验提供建议.

主要方法:

关于DLBCL液体活检的当前文献的综述.
专注于循环中的核酸作为生物标志物.
临床实用性和潜在应用的分析.

主要成果:

液体活检为癌症信号检测提供了一种最小侵入性的替代方案.
循环中的核酸显示出在DLBCL中改善风险分层的潜力.
液体活检的进步可以支持个性化和风险适应的治疗策略.

结论:

液体活检,特别是通过循环的核酸,对DLBCL具有显著的临床潜力.
这种方法可以增强风险分层,并指导个性化治疗决策.
建议进行进一步的生物标记指导试验,以将液体活检纳入临床实践.

关键词:

生物标志物生物标志物疾病监测疾病监测液体活检活检液体活检淋巴瘤淋巴瘤是什么风险分层的风险分层.

更多相关视频

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...